Insulin Resistance and PCOS: Pathophysiology, Symptoms, and Long-Term Consequences

By Guillermo Salinas Araya · June 1, 2026 · Educational Material

In 1988, Gerald Reaven delivered the Banting Lecture at the American Diabetes Association, introducing the concept of Syndrome X — what we now recognize as insulin resistance. That presentation forever changed cardiology, endocrinology, and hepatology.

Medical Definition of Insulin Resistance in PCOS

The term insulin resistance in PCOS refers to a clinical condition with diagnostic criteria established in recent medical literature. Understanding it requires distinguishing between the entity itself, its clinical presentations, and its underlying mechanisms. Updated international guidelines have reformulated several of these criteria over the past decade, expanding beyond what conventional clinical practice has yet incorporated.¹

Pathophysiology: How It Develops

The pathophysiological cascade of insulin resistance in PCOS involves multiple parallel mechanisms that create feedback loops. The single-cause hypothesis has been replaced by integrative models that recognize the interaction of several axes:²

• Endocrine-metabolic axis: impaired insulin sensitivity and hepatic lipogenesis.
• Inflammatory axis: low-grade pro-inflammatory cytokines (TNF-α, IL-6, elevated high-sensitivity CRP).
• Mitochondrial axis: respiratory chain dysfunction and increased reactive oxygen species.
• Intestinal axis: microbiome disruption, increased intestinal permeability, endotoxin translocation.
• Neuroendocrine axis: dysregulation of the hypothalamic-pituitary-adrenal axis with chronically elevated cortisol.

The simultaneous accumulation of these five impacts distinguishes the pathological state from the physiological state of compensatory tolerance. A patient may spend years with one or two active axes without clinical manifestation — until convergence overwhelms adaptive mechanisms.

Clinical Signs and Symptoms

Clinical presentation is heterogeneous. In early stages, most patients are oligosymptomatic or asymptomatic.³ Signs and symptoms that guide diagnosis include:

• Unexplained fatigue, especially postprandial
• Progressive increase in waist circumference
• Skin changes (dark patches, skin tags, hair alterations)
• Sleep-wake cycle disturbances
• Neurocognitive symptoms: brain fog, difficulty concentrating, irritability
• Nonspecific laboratory findings: slightly elevated CRP, mild hepatic or lipid abnormalities frequently labeled as "high normal"
• Subtle ultrasound findings requiring targeted examination

Consequences Without Intervention

The natural history of insulin resistance in PCOS without adequate intervention involves silent but predictable progression:⁴

• Increased cardiovascular risk independent of cholesterol levels
• Accelerated development of type 2 diabetes in patients with prediabetes
• Progression toward structural organ damage within 5 to 15 years
• Increased cancer risk documented in longitudinal cohorts
• Progressive functional decline that reduces quality of life and healthy life expectancy

The therapeutic window of opportunity — the period during which the condition is completely reversible — is proportional to exposure time and the number of compromised pathophysiological axes. Each year lost without comprehensive intervention narrows that window.

Can It Be Reversed?

Contemporary clinical evidence is clear: in pre-irreversible stages, reversal is possible. But it requires addressing all five pathophysiological axes simultaneously, not sequentially or in isolation. This is where conventional approaches fail: they intervene on a single axis and leave the other four active.

The educational protocol we designed — The Salinas Method — comprises 8 sequential phases. Each phase addresses a distinct mechanism in the cascade. Phases 1 and 2 prepare the cellular terrain and correct the microbiome. Phases 3 through 6 dismantle low-grade inflammation, mitochondrial dysfunction, insulin resistance, and cortisol axis disruption. Phases 7 and 8 consolidate the change and prevent recurrence.

It's not a diet. It's not isolated fasting. It's not a supplement. It's a guided educational protocol, step by step, based on the most recent clinical evidence and designed so the patient understands the rationale behind each action.

References

1. DeFronzo RA. Insulin resistance: a multifaceted syndrome. Diabetes Care. 1991. PubMed
2. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988. PubMed
3. Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function. Diabetologia. 1985. PubMed
4. Petersen KF, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018. PubMed
5. Stumvoll M, et al. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005. PubMed
6. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways. Cell. 2012. PubMed